Crestor to be divested to Grünenthal in Europe
1 December 2020 07:00 GMT Crestor to be divested to Grünenthal in Europe AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal GmbH (Grünenthal). Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients.